Future Therapies of Wet Age-Related Macular Degeneration

Table 1

Summary of neovascular AMD therapeutic agents, mechanisms, route, and phase of development.

Agent	Mechanism	Treatment	Phase
E10030	Platelet-derived growth factor (PDGF) inhibitor	iv	3
Sirolimus	Mammalian target of rapamycin (mTOR) inhibitor	iv; sc	2
Infliximab	Anti-tumor necrosis factor alpha (TNF-) antibody	iv	1
POT-4	Complement component 3 (C3) inhibitor	iv	2
JSM6427	Integrin receptor antagonist	iv	1
Volociximab	Anti-v1 integrin monocle antibody	iv	1
ALG-1001	Integrin receptor antagonist	iv	2a
ATG003	Nicotinic acetylcholine receptor (nAchR) antagonist	Eye drop	2
AdPEDF.11	Transgene for cDNA of human PEDF	iv	1
Methotrexate	Antifolate drug	iv	—
Triple combination therapy (verteporfin-ranibizumab-dexamethasone)	Targeting multiple components of choroidal neovascularization	iv; (ranibizumab, dexamethasone); after VPDT	2

iv: intravitreal injection; sc: subconjunctival injection.
VPDT: verteporfin photodynamic therapy.